Xencor | XNCR - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 11.69B 6.9B 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Biogen USD 2.32B 663.6M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Cytokinetics USD 207.8M 7.22M 2026-06
GlaxoSmithKline GBP 6.03B 227M 2026-09
J&J USD 18.93B 1.09B 2026-09
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 10.75B 5.02B 2026-09
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Roche Holding CHF 18.9B 2.12B 2026-06
Xencor USD 87.82M 5.44M 2026-06